文献速递乳腺癌支持与姑息治疗

三十年间癌症治疗变化与女性儿童癌症幸存者后续乳腺癌风险的关联:儿童癌症幸存者研究报告

Association of Changes in Cancer Therapy Over 3 Decades With Risk of Subsequent Breast Cancer Among Female Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study (CCSS).
PubMed 文献 · JAMA Oncol · 2022-10-13

该回顾性队列纳入1970至1999年确诊的11550例女性儿童癌症5年幸存者,随访至2020年12月5日。乳腺浸润癌发生率随原发癌诊断年代每5年下降18%(RR 0.82),调整胸部放疗后降至11%(RR 0.89),再调整蒽环类剂量和盆腔放疗后为14%(RR 0.86)。

要点

  • 幸存者乳腺癌风险高于一般人群,SIR为6.6(95%CI 6.1-7.2)。
  • 浸润性乳腺癌发生率随诊断年代每5年下降18%(RR 0.82;95%CI 0.74-0.90)。
  • 调整胸部放疗后下降幅度减至11%(RR 0.89;95%CI 0.81-0.99)。

核心结论

  • 儿童癌症幸存者浸润性乳腺癌发生率随时间下降,尤其在40岁以下人群中。
  • 该下降似乎主要与胸部放疗使用减少相关,但被其他治疗方式的同步变化所削弱。

研究设计与样本

  • 回顾性队列研究,纳入1970至1999年间确诊时年龄小于21岁的5年癌症幸存者,随访至2020年12月5日。
  • 共纳入11550例女性幸存者,中位年龄34.2岁(范围5.6-66.8岁);489例发生583次乳腺癌(427例浸润性,156例导管原位癌)。

主要发现

  • 至45岁时乳腺癌累积发生率为8.1%(95%CI 7.3%-9.0%)。
  • 与年龄、性别、日历年匹配的一般人群相比,幸存者乳腺癌风险升高,SIR为6.6(95%CI 6.1-7.2)。
  • 按年代划分的治疗变化包括胸部放疗比例下降(1970年代34%、1980年代22%、1990年代17%)和盆腔放疗比例下降(分别为26%、17%、13%),蒽环类化疗暴露比例上升(分别为30%、51%、64%)。
  • 调整年龄和诊断时年龄后,浸润性乳腺癌发生率在原发癌诊断年代每5年下降18%(RR 0.82;95%CI 0.74-0.90)。
  • 进一步调整胸部放疗暴露后,下降幅度减至每5年11%(RR 0.89;95%CI 0.81-0.99);再额外调整蒽环类剂量和盆腔放疗后,每5年下降幅度为14%(RR 0.86;95%CI 0.77-0.96)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Breast cancer is the most common invasive subsequent malignant disease in childhood cancer survivors, though limited data exist on changes in breast cancer rates as primary cancer treatments have evolved. OBJECTIVE: To quantify the association between temporal changes in cancer treatment over 3 decades and subsequent breast cancer risk. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 5-year cancer survivors diagnosed when younger than 21 years between 1970 and 1999, with follow-up through December 5, 2020. EXPOSURES: Radiation and chemotherapy dose changes over time. MAIN OUTCOMES AND MEASURES: Breast cancer cumulative incidence rates and age-specific standardized incidence ratios (SIRs) compared across treatment decades (1970-1999). Piecewise exponential models estimated invasive breast cancer and ductal carcinoma in situ (DCIS) risk and associations with treatment exposures, adjusted for age at childhood cancer diagnosis and attained age. RESULTS: Among 11 550 female survivors (median age, 34.2 years; range 5.6-66.8 years), 489 developed 583 breast cancers: 427 invasive, 156 DCIS. Cumulative incidence was 8.1% (95% CI, 7.3%-9.0%) by age 45 years. An increased breast cancer risk (SIR, 6.6; 95% CI, 6.1-7.2) was observed for survivors compared with the age-sex-calendar-year-matched general population. Changes in therapy by decade included reduced rates of chest (34% in the 1970s, 22% in the 1980s, and 17% in the 1990s) and pelvic radiotherapy (26%, 17%, and 13% respectively) and increased rates of anthracycline chemotherapy exposures (30%, 51%, and 64%, respectively). Adjusting for age and age at diagnosis, the invasive breast cancer rate decreased 18% every 5 years of primary cancer diagnosis era (rate ratio [RR], 0.82; 95% CI, 0.74-0.90). When accounting for chest radiotherapy exposure, the decline attenuated to an 11% decrease every 5 years (RR, 0.89; 95% CI, 0.81-0.99). When additionally adjusted for anthracycline dose and pelvic radiotherapy, the decline every 5 years increased to 14% (RR, 0.86; 95% CI, 0.77-0.96). Although SIRs of DCIS generally increased over time, there were no statistically significant changes in incidence. CONCLUSIONS AND RELEVANCE: Invasive breast cancer rates in childhood cancer survivors have declined with time, especially in those younger than 40 years. This appears largely associated with the reduced use of chest radiation therapy, but was tempered by concurrent changes in other therapies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Henderson TO, Liu Q, Turcotte LM, et al. Association of Changes in Cancer Therapy Over 3 Decades With Risk of Subsequent Breast Cancer Among Female Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study (CCSS). JAMA Oncol. 2022. PMID: 36227603. doi:10.1001/jamaoncol.2022.4649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。